Efficacy and safety of Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia： a Meta-analysis
10.11886/scjsws20221018001
- VernacularTitle:甜梦口服液治疗抗精神病药物所致女性精神分裂症患者高泌乳素血症效果和安全性的Meta分析
- Author:
Xianjun LAN
1
;
Zhenjuan QIN
1
;
Qiman LIU
2
;
Dongbin CAI
3
;
Yaoyao LU
1
;
Xiong HUANG
2
;
Wei ZHENG
2
Author Information
1. Brain Hospital of Guangxi Zhuang Autonomous Region， Liuzhou 545005， China
2. The Affiliated Brain Hospital of Guangzhou Medical University， Guangzhou 510370， China
3. Shenzhen Traditional Chinese Medicine Hospital， Shenzhen 518000， China
- Publication Type:Journal Article
- Keywords:
Tianmeng Oral Liquid;
Schizophrenia;
Hyperprolactinemia;
Meta-analysis
- From:
Sichuan Mental Health
2023;36(1):25-31
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo systematically evaluate the efficacy and safety of Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia， and to provide references for intervention of antipsychotic-induced hyperprolactinemia patients. MethodsEnglish databases （PubMed， Cochrane Library， PsycINFO and Embase） and Chinese databases （CNKI and Wanfang） were systematically searched， with a search time frame of the period from database creation to September 16， 2022. Randomized controlled studies （RCTs） on adjunctive Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia were included. Three investigators independently screened the literatures and extracted data according to PICOS principles and evaluated the quality of including literatures， and the Meta-analysis was performed by using RevMan 5.3. ResultsA total of 3 articles including 256 female schizophrenic patients with hyperprolactinemia were included. Meta-analysis results showed that at the treatment endpoint， the improvement of hyperprolactinemia symptoms reported a significant superiority of the intervention group than the control group （RR=1.73， 95% CI： 1.07~2.79， P˂0.05）. Similarly， the significant superiority of the intervention group than the control group were also found in reducing serum prolactin levels （WMD=-55.17， 95% CI： -68.16~-42.18， P<0.01） and Positive and Negative Syndrome Scale （PANSS） total scores were lower in the intervention group than in the control group （WMD=-7.36， 95% CI： -8.94~-5.77， P<0.01）. ConclusionTianmeng Oral Liquid may help improve clinical efficacy and reduce serum prolactin levels in female schizophrenia patients with hyperprolactinemia. It may improve psychiatric symptoms in female patients with schizophrenia.
